Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a research report report published on Saturday. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

CO stock opened at $0.80 on Friday. Global Cord Blood has a one year low of $2.03 and a one year high of $5.50. The stock has a market cap of $97.24 million, a price-to-earnings ratio of 1.25 and a beta of 0.16. The company has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $1.25.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.